You’ll Never Guess Who the FDA is Using for New ADHD Drug Testing

Shire , a research and development corporation that specializes in marketing “specialty medicines for symptomatic conditions to meet significant unmet patient needs”, has been asked by the Food and Drug Administration (FDA) to conduct clinical trials of Vyvanse, a pharmaceutical drug marketed to children for the treatment of attention deficit hyperactivity disorder (ADHD).

Because more than 10,000 toddlers age 2 or 3 are medicated for ADHD with Ritalin or Concerta; preschool-aged children have proven to be a prime target for pharmaceutical corporations.

Shire will begin clinical trials on pre-school aged children in 2015 because the company is “committed to continuing to add to the scientific body of knowledge about ADHD treatment options for patients.”

Read more: ADHD Drug Trials on Pre-Schoolers